Regeneron Pharmaceuticals, Inc
Regeneron Pharmaceuticals is a U.S.-based biotechnology company that discovers, develops, manufactures, and commercializes medicines for serious diseases. Its business combines internal research, clinical development, biologics manufacturing, and product commercialization, with a portfolio that includes marketed therapies and a pipeline of product candidates.
Fiscal year 2025 · change from previous year
Development 2020–2025
Business
Share of revenueRetinal disease medicines, including EYLEA HD and EYLEA, used in eye care indications.
Partnered and co-commercialized therapies such as Dupixent and Kevzara for immune-mediated diseases.
Cancer therapies including Libtayo and related oncology development programs.
Lipid-lowering and cardiovascular-related products such as Praluent.
Profit-sharing, royalties, and manufacturing reimbursement from partners such as Sanofi and Bayer.
Products
Reported · share of revenue- Collaboration Revenue51.1 %
- Products44.0 %
- Other4.9 %
Source: 10-K FY2025, revenue the company reports per product line (SEC XBRL). Shares are of the lines shown and add up to 100 %.
Customers
Regeneron sells primarily to distributor customers, specialty pharmacies, and healthcare providers through the U.S. pharmaceutical distribution channel. A large portion of gross product revenue is concentrated in two distributor customers, while some products are commercialized globally through partners such as Sanofi and Bayer. Demand is ultimately driven by physicians, hospitals, and specialty care settings treating serious chronic and acute diseases.
Large U.S. distributors and specialty pharmacies buy product inventory and resell to providers and pharmacies.
Physicians, clinics, and hospitals prescribe and administer Regeneron's medicines to patients.
Specialty pharmacies handle distribution for biologics and other specialty medicines.
Partners such as Sanofi and Bayer commercialize certain products and share profits or royalties.
Private insurers and government programs determine coverage and reimbursement access.
Strategy
Regeneron's strategy centers on internal discovery, clinical development, and commercialization of biologic medicines for serious diseases, supported by a large pipeline of homegrown candidates. It also relies on collaborations to extend reach, share development/commercialization economics, and support global product access for selected therapies.
Commercial success of EYLEA HD, EYLEA, and Dupixent is central to the business model.
A large internal pipeline is needed to replenish and diversify future revenue sources.
Biologics require reliable production, fill/finish, and distribution capacity.
Partnered products contribute profit share, royalties, and manufacturing reimbursement.
Geography
Regeneron is headquartered in the United States and records net product sales in the U.S. through distributor and specialty pharmacy channels. Outside the United States, key products are commercialized through partners such as Bayer and Sanofi, which creates meaningful international exposure even when Regeneron does not book direct product sales in those markets.
Risks
Regeneron depends heavily on a small number of marketed products and on reimbursement access, so commercial concentration can quickly affect results. The company also faces typical biotech risks around clinical failure, regulatory delay, patent loss, biosimilar competition, and manufacturing complexity, all of which can reduce exclusivity or interrupt supply.
- Reimbursement and pricing pressureImpact: HighLikelihood: High
Payor coverage and copay support determine patient access and net sales.
Exposure - Biosimilar and competitive erosionImpact: HighLikelihood: High
Competing products can be more cost effective or easier to administer.
Exposure: Ophthalmology and immunology franchises
- Product concentrationImpact: HighLikelihood: Medium
A large share of revenue depends on a few marketed therapies.
Exposure - Distributor customer concentrationImpact: HighLikelihood: Medium
Two customers account for most gross product revenue, creating channel risk.
Exposure: U.S. distributor and specialty pharmacy channel
- Regulatory and development failureImpact: HighLikelihood: Medium
Drug development is costly, uncertain, and subject to approval risk.
Exposure: Clinical pipeline and new indications
- Manufacturing and supply chain disruptionImpact: MediumLikelihood: Medium
Biologics require complex production, fill/finish, and distribution steps.
Exposure: Commercial supply and launch readiness
Accounting
Judgemental itemsSanofi and Bayer arrangements include profit share and reimbursement components that vary with partner sales and costs.
Impact: Affects collaboration revenue and comparability across periods
Gross-to-net deductions such as rebates, chargebacks, returns, and copay assistance require judgment.
Impact: Affects reported product revenue and margins
Large distributor customers drive a significant portion of receivables and sales channel risk.
Impact: Affects credit loss exposure and revenue timing
Pipeline success, patent life, and biosimilar competition can influence impairment and capitalization assumptions.
Impact: Affects asset values and future expense recognition
Similar listed companies
Publicly listed companies with a comparable business focus.
Regen BioPharma Inc
RGBPP · Pharmaceutical Preparations
Regen BioPharma Inc is a U.S.-based biopharmaceutical development company organized in Nevada and operating through its wholly owned subsidiary KCL Therapeutics, Inc.
Regenerex Pharma, Inc.
Pharmaceutical Preparations
Vincerx Pharma, Inc.
Pharmaceutical Preparations
Geron Corporation
GERN · Pharmaceutical Preparations
Geron Corp is a U.S.-based biopharmaceutical company focused on developing and commercializing imetelstat, marketed as RYTELO, for patients with lower-risk myelodysplastic syndromes.
Regencell Bioscience Holdings Ltd
RGC · Medicinal Chemicals & Botanical Products
Regencell Bioscience Holdings Ltd is a Hong Kong-based bioscience company focused on developing botanical and medicinal chemical formulations.
Rigel Pharmaceuticals, Inc
RIGL · Pharmaceutical Preparations
Rigel Pharmaceuticals is a U.S.-based biotechnology company focused on therapies for hematologic disorders and cancer.
Last updated: 24/09/2026